70 studies found for:    "Autosomal dominant polycystic kidney disease"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Withdrawn Repository Study of Autosomal Dominant Polycystic Kidney Disease
Condition: Autosomal Dominant Polycystic Kidney Disease
Intervention:
2 Completed Adrenal Functions in Autosomal Dominant Polycystic Kidney Disease
Condition: Autosomal Dominant Polycystic Kidney Disease
Intervention: Drug: Tetracosactin
3 Terminated Sirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal Insufficiency
Condition: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions: Drug: Sirolimus;   Drug: conventional therapy
4 Completed Sirolimus (Rapamune®) for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Condition: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions: Drug: Sirolimus;   Other: Standard
5 Completed New Quantitive MRI Parameters in Assessing Kidneys of Autosomal Dominant Polycystic Kidney Disease
Conditions: Autosomal Dominant Polycystic Kidney Disease;   Kidney Disease
Intervention:
6 Completed 8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Condition: Autosomal Dominant Polycystic Kidney Disease
Interventions: Drug: Tolvaptan MR;   Drug: Tolvaptan IR;   Drug: Placebo
7 Enrolling by invitation Open-label Trial to Evaluate the Long Term Safety of Titrated Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
Condition: Autosomal Dominant Polycystic Kidney Disease
Intervention: Drug: Tolvaptan (OPC-41061)
8 Active, not recruiting Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease
Conditions: Chronic Kidney Disease;   Autosomal Dominant Polycystic Kidney Disease
Interventions: Drug: Tolvaptan (OPC-41061);   Drug: Placebo
9 Completed
Has Results
Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease
Condition: Autosomal Dominant Polycystic Kidney Disease
Interventions: Drug: Placebo;   Drug: Everolimus
10 Completed Water as Therapy in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Condition: Autosomal Dominant Polycystic Kidney Disease
Intervention: Other: Water prescription
11 Unknown  Triptolide-Containing Formulation as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Condition: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions: Drug: Triptolide-Containing Formulation;   Drug: Placebo
12 Completed A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001]
Condition: Autosomal Dominant Polycystic Kidney Disease
Intervention: Drug: OPC-41061
13 Completed Observational Study in Patients With Autosomal Dominant Polycystic Kidney Disease
Condition: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Intervention:
14 Completed A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]
Condition: Autosomal Dominant Polycystic Kidney Disease
Intervention: Drug: OPC-41061
15 Active, not recruiting Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency
Condition: Autosomal Dominant Polycystic Kidney Disease.
Interventions: Drug: Octreotide-LAR;   Other: Saline solution.
16 Not yet recruiting The Safety and Efficacy of Catheter-based Renal Denervation Using the Vessix™ Renal Denervation System in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Patients With Severe Debilitating Pain
Condition: Autosomal Dominant Polycystic Kidney Disease
Intervention: Device: Vessix
17 Completed A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]
Condition: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Intervention: Drug: tolvaptan
18 Terminated
Has Results
Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarkers in Predicting a Response to Therapy
Condition: Autosomal Dominant Polycystic Kidney Disease
Interventions: Drug: Rapamycin;   Other: Standard of Care-Placebo
19 Completed Open-Label Tolvaptan Study in Subjects With ADPKD
Condition: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Intervention: Drug: Tolvaptan
20 Active, not recruiting Clinical Implications of DNA Analysis on ADPKD
Condition: Autosomal Dominant Polycystic Kidney Disease
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years